Karl Claxton

发表

Development goals should enable decision-making.

Jan de Leeuw, Norman Fenton, Keith D. Shepherd, 2015 .

Bayesian econometric modelling of observational data for cost‐effectiveness analysis: establishing the value of negative pressure wound therapy in the healing of open surgical wounds

Nicky J Welton, Karl Claxton, Pedro Saramago, 2020, Journal of the Royal Statistical Society: Series A (Statistics in Society).

Using Meta-Analysis to Plan Further Research

Claire Rothery, Karl Claxton, Susan Griffin, 2020 .

Comparing the Value of Different HTA Decision Making Process: Evaluating the Evaluators

Karl Claxton, Mark Sculpher, Allan Wailoo, 2013 .

Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses

Karl Claxton, Alec Morton, Linda Sharples, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Defining and characterising structural uncertainty in decision analytic models

Karl Claxton, Mark Sculpher, Laura Bojke, 2006 .

Exploring Uncertainty in Cost-Effectiveness Analysis

Karl Claxton, K. Claxton, 2012, PharmacoEconomics.

The NICE cost-effectiveness threshold: what it is and what that means.

Karl Claxton, Christopher McCabe, Anthony J Culyer, 2008, PharmacoEconomics.

Accounting for Timing when Assessing Health-Related Policies

Karl Claxton, Mike Paulden, Julian C. Jamison, 2019, Journal of Benefit-Cost Analysis.

Systematic review of the literature on the cost-effectiveness threshold

Karl Claxton, Nigel Rice, Steve Martin, 2015 .

The Value of Sample Information: A Decision Theoretic Approach to Research Design

Karl Claxton, 2007 .

Probabilistic analysis and computationally expensive models: Necessary and required?

Karl Claxton, Neil Hawkins, Mark Sculpher, 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Expected health benefits of additional evidence: Principles, methods and applications

Karl Claxton, Hendrik Koffijberg, Susan Griffin, 2013 .

Decision Models Need to be “Fit for Purpose” for Decision‐Making: Response to Caro et al.

Karl Claxton, Neil Hawkins, Mark Sculpher, 2007 .

A Framework for Addressing Structural Uncertainty in Decision Models

Karl Claxton, Simon G Thompson, Laura Bojke, 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

Selecting treatments: a decision theoretic approach

Karl Claxton, Larry F. Lacey, Stephen G Walker, 2000 .

Addressing Adoption and Research Design Decisions Simultaneously

Karl Claxton, Claire McKenna, K. Claxton, 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

Using value of information analysis to inform publicly funded research priorities

Karl Claxton, Mark J Sculpher, Laura Ginnelly, 2005, Applied health economics and health policy.

Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.

Karl Claxton, Elisabeth A L Fenwick, Ties Hoomans, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Karl Claxton, Andrew Briggs, Peter McGregor, 2016, Health economics.

Discounting and decision making in the economic evaluation of health-care technologies.

Karl Claxton, Mike Paulden, Anthony J Culyer, 2011, Health economics.

Bayesian approaches to technology assessment and decision making

Karl Claxton, Bryan R. Luce, Ya-Chen Tina Shih, 2001 .

Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses

Nicky J Welton, Karl Claxton, A E Ades, 2007, BMJ : British Medical Journal.

Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations.

Karl Claxton, Nigel Rice, Mark Sculpher, 2009, Health policy.

Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.

Karl Claxton, Mark Sculpher, Simon Walker, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Decision analysis for resource allocation in health care

Karl Claxton, Mark Sculpher, Susan Griffin, 2008, Journal of health services research & policy.

Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions.

Zaid Chalabi, Karl Claxton, Claire McKenna, 2010, Journal of health economics.

Eliciting distributions to populate decision analytic models.

Karl Claxton, Mark Sculpher, Laura Bojke, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Value of Implementation and the Value of Information: Combined and Uneven Development

Karl Claxton, Mark Sculpher, Elisabeth Fenwick, 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery

Karl Claxton, Mark Sculpher, Elisabeth Fenwick, 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence

Karl Claxton, Andrew Briggs, Christopher McCabe, 2007, Journal of health services research & policy.

Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis

Karl Claxton, Mark Sculpher, Elisabeth Fenwick, 2002, Intensive Care Medicine.

The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis

Karl Claxton, Andrea Manca, M. Sculpher, 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.

Karl Claxton, Andrew Briggs, John Brazier, 2006, Health economics.

A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence

Karl Claxton, Christopher McCabe, Paul Tappenden, 2005 .

Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system

Karl Claxton, Andrea Manca, Mark Sculpher, 2018, Health economics.

Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs

Nicky J Welton, Karl Claxton, Susan Griffin, 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Karl Claxton, Milton C Weinstein, Maarten J. IJzerman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse

Karl Claxton, Una Adderley, Nikki Stubbs, 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

Efficiency, Equity, and Budgetary Policies

Zaid Chalabi, Karl Claxton, Mark Sculpher, 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE

Karl Claxton, Christopher McCabe, Allan Wailoo, 2005 .

Surgical wounds healing by secondary intention: characterising and quantifying the problem, identifying effective treatments, and assessing the feasibility of conducting a randomised controlled trial of negative pressure wound therapy versus usual care

Nicky J Welton, Karl Claxton, Dorothy McCaughan, 2019 .

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

Karl Claxton, Mark Sculpher, Beth Woods, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

When is evidence sufficient?

Joshua T. Cohen, Karl Claxton, Joshua T Cohen, 2005, Health affairs.

Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration

Karl Claxton, Mark J Sculpher, Laura Bojke, 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis

Karl Claxton, K. Claxton, C. Iglesias, 2012, PharmacoEconomics.

Wound healing and TIME; new concepts and scientific applications.

Karl Claxton, Gregory Schultz, Marco Romanelli, 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design

Karl Claxton, Stefano Conti, S. Conti, 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Karl Claxton, Nigel Rice, Mark Sculpher, 2015, Health technology assessment.

Assessing Quality in Decision Analytic Cost-Effectiveness Models

Karl Claxton, Mark Sculpher, Elisabeth Fenwick, 2000, PharmacoEconomics.

Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?

Karl Claxton, Mark Sculpher, M. Sculpher, 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.

Claire Rothery, Karl Claxton, Mark Sculpher, 2017, Health economics.

Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?

Karl Claxton, Mark Sculpher, Stephen Palmer, 2015, Health economics.